Skip to main content
ConductScienceScienceDex

Kenneth Schultz

NIH Rank #2670
Unclaimed recordClaim profile
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 77812017Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2024

Linked Award Amount
$3M
Full award amounts, FY2024
Award Records
5
Records listing this PI
Award-Linked Rank
#2,670
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Kenneth Schultz. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Kenneth Schultz as a PI. Multi-PI records show the full award amount for context.

  • 1R44AI186534-01R44
    Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
    Trethera Corporation
    $1.1M
    award amount
  • 5R44CA281485-02R44
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types
    Trethera Corporation
    $696.6K
    award amount
  • 4R42EY034397-02R42
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
    Trethera Corporation
    $615.9K
    award amount
  • 5R41AI179213-02R41
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
    Trethera Corporation
    $305.7K
    award amount
  • 5R41AI179191-02R41
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
    Trethera Corporation
    $297.1K
    award amount

Award organization

Organizations that administered FY2024 awards listing Kenneth Schultz as a PI.

FY2024 award administered by Trethera Corporation (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Trethera Corporation
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2670
  6. 2024
    Entered Top 25% Nationally
    Ranked #2670
  7. 2025
    $5M Cumulative Funding
  8. 2025
    Entered Top 10% Nationally
    Ranked #1367

Explore further

Find collaborators for Kenneth Schultz

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →